Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study

• Váldodahkkit: Nina Magnolo (Dahkki), Michael C. Cameron (Dahkki), Mona Shahriari (Dahkki), Bob Geng (Dahkki), Brian M. Calimlim (Dahkki), Henrique Teixeira (Dahkki), Xiaofei Hu (Dahkki), Yang Yang (Dahkki), Yingyi Liu (Dahkki), Shiyu Zhang (Dahkki), Cristina Sancho Sanchez (Dahkki), Katherine Altman (Dahkki), Richard G. Langley (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

AbstractPurpose: Atopic dermatitis (AD) adversely impacts quality of life (QoL). We evaluated the effect of upadacitinib, an oral selective Janus kinase inhibitor approved for moderate-to-severe AD, plus topical corticosteroids (+TCS) on patient-reported outcomes (PROs) over 52 weeks.Materials and m...